Published in Lancet Oncol on November 20, 2009
Current management of gallbladder carcinoma. Oncologist (2010) 1.83
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol (2015) 1.63
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol (2010) 1.30
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget (2015) 1.02
Gallbladder Cancer in the 21st Century. J Oncol (2015) 1.02
Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol (2012) 0.97
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs (2010) 0.96
Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J (2013) 0.96
Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res (2011) 0.92
18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging (2011) 0.92
Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med (2013) 0.92
What is the relationship between ¹⁸F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J Nucl Med Mol Imaging (2011) 0.91
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat (2015) 0.90
A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother (2013) 0.88
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget (2016) 0.87
Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterol Res Pract (2015) 0.87
Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol (2016) 0.86
Current therapy and future directions in biliary tract malignancies. Curr Treat Options Oncol (2013) 0.86
Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) (2011) 0.86
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol (2015) 0.86
New and emerging treatment options for biliary tract cancer. Onco Targets Ther (2013) 0.85
EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma. PLoS One (2013) 0.84
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget (2010) 0.84
Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol (2013) 0.84
Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. Oncologist (2015) 0.83
CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. AJR Am J Roentgenol (2015) 0.83
Targeted Therapy in Biliary Tract Cancers. Curr Treat Options Oncol (2015) 0.83
AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther (2013) 0.83
Development of radiotracers for oncology--the interface with pharmacology. Br J Pharmacol (2011) 0.81
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol (2014) 0.81
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol (2014) 0.81
Optimum chemotherapy for the management of advanced biliary tract cancer. World J Gastroenterol (2015) 0.80
Targeted therapy for biliary tract cancer. Cancers (Basel) (2011) 0.80
Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma. J Gastrointest Surg (2012) 0.79
Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer (2010) 0.79
Chemotherapy and targeted therapy for gall bladder cancer. Indian J Surg Oncol (2014) 0.77
Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment. World J Surg Oncol (2014) 0.76
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci (2017) 0.75
Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res (2013) 0.75
Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol (2011) 0.75
Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. BMC Cancer (2017) 0.75
A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report. Surg Case Rep (2016) 0.75
Targeted therapy for biliary-tract cancer. Lancet Oncol (2010) 0.75
Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: A meta-analysis. World J Gastroenterol (2015) 0.75
Systemic Therapy of Cholangiocarcinoma. Visc Med (2016) 0.75
Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol (2016) 0.75
Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr (2017) 0.75
Progression of targeted therapy in advanced cholangiocarcinoma. Chin J Cancer Res (2015) 0.75
Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol (2017) 0.75
Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Br J Cancer (2017) 0.75
Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol (2017) 0.75
Targeted therapy in biliary tract cancers-current limitations and potentials in the future. J Gastrointest Oncol (2017) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med (2010) 29.06
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Translating the A1C assay into estimated average glucose values. Diabetes Care (2008) 11.55
The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res (2004) 10.47
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst (2006) 7.19
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine (2009) 6.30
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res (2004) 6.04
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell (2011) 5.91
Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med (2006) 5.24
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol (2012) 4.28
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06
Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
[Human natural infection of Plasmodium knowlesi]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2006) 3.99
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol (2011) 3.96
Association of nut consumption with total and cause-specific mortality. N Engl J Med (2013) 3.94
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (2010) 3.60
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst (2004) 3.49
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature (2012) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39